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Abstract
The fatty acid receptor peroxisome proliferator-activated receptor gamma (PPARγ) is a transcription factor, which includes two 
isoforms named PPARγ1 and PPARγ2 respectively. In human body, PPARү involves in metabolic disorder, neurodegenerative disease 
and inflammation. Recent advance in PPARү study has led to the discoveries of several genes that are regulated by PPARγ in prostate 
cancer cells. Evidence showed that PPARү plays important roles in development and in malignant progression of prostate cancer. 
In this mini-review, we described the PPARγ structure and summarized their involvement in different diseases. Our focus is on the 
roles of PPARγ isoforms in prostate cancer.
Peroxisome Proliferator-Activated Receptor Gam-
ma 
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) is 
a transcription factor that is ligand dependent and is a member of the 
nuclear hormone receptor superfamily. PPARγ is expressed in two 
isoforms: PPARγ1 and PPARγ2, the latter contains thirty extra amino 
acids (Figure 1). Both synthetic and endogenous ligands can band to 
and activate PPARγ [1]. When activated, PPARγ is translocated into 
the nucleus and forms a heterodimer with the retinoid X receptor 
(RXR), where it serves as a transcriptional regulator of genes via 
DNA binding [2]. It is well established that PPARγ plays a critical 
role in adipocyte differentiation, the inflammatory response, and 
peripheral glucose consumption. PPARγ agonists are frequently 
utilised to treat type II diabetes [1]. Diabetes type II is the most 
prevalent endocrine-metabolic condition worldwide, characterised 
by insulin resistance and insulin secretion abnormalities. PPARγ 
agonists were utilised to sensitise tissues (muscle, adipose tissue, 
and liver) to insulin stimulation. However, these PPARγ agonist 
medicines were associated with significant side effects such as 
increased weight, oedema, heart failure, and an increased risk of 
myocardial infarction [3]. The role of PPARү in prostate cancer 
(PCa) has been controversial. Initially, it was believed that PPARγ 
 
functioned as a tumour suppressor in prostate cells since agonist 
ligands suppressed the proliferation of PCa cells. However, further 
investigations revealed that these agonists suppressed cell growth 
in a manner independent of PPARγ [4-8]. Furthermore, PPARγ 
expression rises with the grade/stage of cancer cases [9-11]. 
These results suggested that it is not a tumour suppressor. In the 
contrary, studies also find PPARγ activity may contribute to the 
development and the progression of the prostate cancer. While a 
tumour suppressor expression level frequently reduced as the 
develop and progress of the malignancies, PPARγ expression level 
appeared to be significantly increased with elevated PCa stage and 
grade, strongly implying that it is cancer-promoter or oncogene. 
For example, it was discovered by immunohistochemical staining 
that PPARγ expression was significantly greater and more intense 
in prostate cancer and prostatic intraepithelial neoplasia (PIN) 
tissues than in benign prostatic hyperplasia (BPH) and normal 
prostate tissues samples [11]. Similarly, utilising more tissue 
samples in a separate investigation by a different group, it was 
discovered that PPARγ expression was substantially higher in 
advanced PCa tissues than in low-risk PCa and BPH specimens (P 
<0.001) [10]. In addition, two smaller investigations found higher 
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PPARγ expression in malignant versus benign tissues [12,13]. When 
taken all these studies together, these findings strongly suggested 
that PPARγ is not a tumour suppressor and that its activation may 
play a promotive role in the development of PCa.
Figure 1: Structures of PPARγ1 and PPARγ2. At protein level, PPARγ consists of an activation function 1 (AF-1) region, a 
variable or Hinge (A/B) region, a DNA-binding domain (DBD). a ligand-binding domain (LDB), and an activation function 2 
(AF-2) region. PPARγ2 has an extra of 30 Amino acids.
The Role of PPARγ in PCa
Using a Sleeping Beauty screen in prostate-specific Pten/ mice, 
Ahmad et al. identified PPARγ as a new gene that promoted prostate 
carcinogenesis [9]. In comparison to littermate controls, mice 
having insertions upstream of the PPARγ gene that increased PPAR 
protein expression had lower survival rate with increased lung 
and lymph node metastases [9]. In these animals, increased PPARγ 
expression was correlated with increasing expression of PPARγ 
targeting genes for FASN, ATP citrate lyase (ACYL), and acetylCoA 
carboxylase (ACC) [9]. Overexpression of PPARγ promoted cell 
proliferation and migration in three PCa cell lines, DU145, PC3, and 
PC3M, while siRNA knockdown of PPAR had the opposite effect 
[9] Ahmad et al. also discovered a significant positive correlation 
between PPARγ levels and PCa grades, as well as a link between low 
PTEN expression and poor disease-specific survival in patients with 
low PTEN expression [9]. Furthermore, Ahmad et al. also analysed 
data from the cBioportal (www.cbioportal.org) and discovered that 
the PPARγ gene was amplified in 26% of advanced cancers and that 
the enzyme 15lipoxygenase 2 (ALOX15B), an endogenous PPARγ 
ligand, which reconstructs 15S hydroxyeicosatetraenoic acid, was 
upregulated in an extra 17% of cases [9]. Additionally, over half of 
all sequenced tumours expressed one or more of the PPAR target 
genes for FASN, ACC, or ACLY, strongly suggested a promotive role 
for PPARγ activation in the development and progression of PCa [9].
 One of the very first studies to examine the involvement of 
PPAR in PCa was motivated by the fact that diets high in omega-3 
fatty acids appear to be associated with a reduced incidence of 
PCa than diets high in omega-6 fatty acids. One of these fatty acid 
metabolites, 15-Deoxy-Δ12,14-prostaglandin J2 (15dPGJ2), is a 
particular PPAR activator [14] and was found to have anticancer 
activity [15], prompting Butler et al. to investigate if the antitumor 
qualities were attributable to PPAR activation [16]. They discovered 
that while 15dPGJ2 and other PPARγ activators such as ciglitazone 
promoted cell death in three PCa cell lines, PPARα and β ligands 
did not. This initial discovery sparked more research on the 
usefulness of PPARγ activating ligands in PCa, which revealed that 
PPARγ agonists reduced androgen receptor (AR) level and activity 
while inhibiting PCa cell growth [17-19]. Furthermore, further 
mechanistic studies proved unequivocally that these compounds 
had an impact independent of the PPARγ (Figure 1.17). According 
to one study, PPAR agonists reduced cell proliferation by promoting 
the proteasomal degradation of transcription factor specificity 
protein 1. (SP1) [20].  Other studies suggested alternative 
mechanisms by which PPARγ agonists inhibited PCa cell growth in a 
PPARγ-independent manner, which include the inhibition of BclxL/
Bcl2 functions [21], the inhibition of the CXC chemokine receptor 
type 4/CXC motif chemokine 12 (CXCR4/CXCL12) axis [22], and 
the inhibition of the AKT signalling pathway [23]. A further study 
indicated that PPARγ agonists promoted AR signalling in C42 PCa 
cells, and that this was PPARγ dependent [24].  As a result, it is 
probable that PPARγ agonists stimulate AR signalling, but their 
effects on SP1 or other pathways in some cell types result in indirect 
AR suppression and lower PCa cell growth. The role of PPARγ and 
its ligands in PCa development can be shown in [Figure 2].
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Figure 2:  The role of PPARγ and its ligands in PCa growth: PPARγ has an oncogenic role in the development and progression 
of PCa through both AR-dependent and AR-independent mechanisms.  PPARγ agonists were found to reduce PCa cell growth 
through PPARγ-independent pathways. PPARγ antagonists may be useful in treatment of advanced PCa as well as the 
prevention of PCa. PPARγ: peroxisome proliferator activated receptor gamma, AR: androgen receptor, SP1: specificity protein 
1, and PC: prostate cancer.
Previous work demonstrated that elevated FABP5 levels 
contributed significantly to malignant progression in castration-
resistant PC (CRPC) model cell systems by binding and transferring 
larger amounts of fatty acids, which stimulated the nuclear receptor 
PPARγ [26]. It is also demonstrated that treatment of PC3-M cells 
with PPARγ antagonist GW9662 resulted in a similar inhibition of 
tumour growth to that observed with a FABP5 inhibitor named 
dmrFABP5. These results suggested that the inhibitory mechanism 
of dmrFABP5 is connected to the FABP5-PPARγ-signaling pathway 
[27]. Experiments proved that the cellular uptake of fatty acids 
was increased as the increasing malignancy of the tested PCa cells, 
indicating that increased amounts of fatty acids were taken up by 
the cancer cells and that at least some of excessive amount of fatty 
acids was used as signalling molecules to stimulate and thus to 
activate PPARγ [28]. Chemically synthesized FABP5 inhibitor SB-
FI-26 was shown to reduce significantly the amount of fatty acids 
uptake into PC3M cells. So, it was suggested that SB-FI-26 acts as a 
competitive inhibitor of fatty acids for FABP5 and thus inhibited the 
transport of intra- and extracellular fatty acids into the cytoplasm 
[29]. It was suggested that the competitive inhibition of fatty acid 
uptake by SB-FI-26 may result in a deacress or discontinuation 
of fatty acid-induced PPARγ activation. Thus, PPARγ may lose its 
ability to upregulate downstream cancer-promoting genes (such 
as VEGF), or to downregulate downstream tumour-suppressor 
genes (such as apoptotic genes) [27, 28].  Previous investigation 
demonstrated FABP5-PPAR-VEGF signalling axis, rather than the 
AR-initiated pathways, is the predominant pathway for malignant 
signal transduction in CRPC cells [27]. Therefore, PPARγ seems 
to play a critical role in this axis. Interestingly, the bio-inhibitor 
dmrFABP5 was much stronger than the chemical inhibitor SB-
FI-26 in suppressing CRPC developed in nude mice, unlike SB-
FI-26, dmrFABP5 did not have an inhibitive effect in cellular fatty 
acid uptake [28].
Role of PPARγ isoforms in prostate cancer   
Because PPARγ agonists reduce AR activity and PCa cell 
proliferation, it was initially assumed to be tumour suppressors in 
prostate cells [30-34]. But, PPARγ agonists, on the other hand, were 
shown to suppress cell growth and AR activity in an independent 
manner of PPAR activity [35-37]. In addition, PPARγ expression also 
rises with PC grade/stage [38-40], indicating that the opposite to 
the initial assumption is true. In order to study PPARγ as a functional 
target in PCa, it is vital to notice the fact that PPARγ has two 
isoforms. PPARγ2 which looks exactly like PPARγ1,  but is 30 amino 
acids longer than PPARγ1 at the amino terminus. PPARγ1 is found 
in many organs, whereas PPARγ2 is found primarily in adipocytes 
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and regulates their differentiation [40, 41]. A recent study by Strand 
et al [42]. revealed that the two PPARγ isoforms had significant 
variations. In this study, the PPAR gene was first knocked out in 
mouse prostate epithelial cells, and then the individual PPARγ1 and 
PPARγ2 transcripts were subsequently reintroduced. When these 
modified cells were used in a prostate reconstitution assay, it was 
discovered that restoring PPARγ1 resulted in the development of 
adenocarcinoma, whereas restoring PPARγ2 led to the formation 
of benign glands. According to a recent study, in many but not all 
local and metastatic malignancies, both isoforms of PPARγ are 
expressed in human tissue, with PPARγ1 predominating in PCa 
cells. Researchers further show that both PPARγ1 and PPARγ2 
are expressed in epithelial cells of isolated benign prostate glands 
using IHC and RNA in situ hybridization. These results suggested 
that PPARγ1 is more important than PPARγ2 in the malignant 
progression of PCa. Indeed, such functional characterisation 
tests by Strand et al [42]. clearly suggested that PPARγ1 had an 
oncogenic capability in prostate cells while PPARγ2 had a tumour 
suppressive property. This conclusion was supported by some 
recent studies [28]. In a mouse prostate reconstitution test, Strand 
et al colleagues clearly proved that expression of PPARγ1 alone in 
benign mouse prostate epithelial cells resulted in the formation of 
adenocarcinoma-like tissue, whereas expression of PPARγ2 alone 
resulted in a highly differentiated phenotype [42]. In the soft agar 
colony formation assay, the addition of PPARγ1, but not PPARγ2, 
boosted the proliferation of BPH1 cells. It was also discovered that 
inhibiting PPARγ1 reduced the proliferation of PCa cell lines with 
endogenous or constitutive expression of PPARγ1. This supports the 
concept that PPARγ1 is an oncogene. The introduction of PPARγ2 
inhibited the proliferation of LNCaP cells, further supporting the 
idea of PPARγ2 as a tumour suppressor.
The functional role of PPARү played in malignant progression 
of PCa cells has been a controversial issue for quite a long time 
[4]. Recent functional characterisation of PPARү isoforms greatly 
facilitated the clarification on the functional roles of this gene. 
However there still are many issues requiring further study on 
PPARү’s functional role in PCa and the underlying molecular 
mechanisms. The recent encouraging advances in more reliable and 
efficient gene-editing techniques, such as crispr/cas9, provided 
better methods to evaluate functional role of PPARү and will help 
the research community to understand this gene better and to 
develop better strategies for therapeutic interventions. 
Acknowledgements 
BTA is supported by a PhD studentship from the Faculty of 
Medicine, Northern Borders University, Saudi Arabia. GH and YK 
are supported by a joint International Cooperation Grant from the 
Science and Technology Department, the Government of Sichuan 
Province, China (Grant Number: 2019YFH0054).
Competing Interest 
The authors declare no conflict of interest.
References
1. Rosen ED, BM Spiegelman (2001) PPAR gamma: a nuclear regulator 
of metabolism, differentiation, and cell growth. Journal of Biological 
Chemistry 276(41): 37731-37734.
2. Ahmadian M, Jae Myoung Suh, Nasun Hah, Christopher Liddle, Annette R 
Atkins, et al. (2013) PPARγ signaling and metabolism: the good, the bad 
and the future. Nat Med 19(5): 557-566.
3. Bermudez V, Freddy Finol, Nailyn Parra, Maria Parra, Adriana Pérez, 
et al. (2010) PPAR-gamma agonists and their role in type 2 diabetes 
mellitus management. Am J Ther 17(3): 274-283.
4. Elix C, SK Pal, JO Jones (2018) The role of peroxisome proliferator 
activated receptor gamma in prostate cancer. Asian J Androl 20(3): 238-
243. 
5. Yang CC, Yu-Chieh Wang, Shuo Wei, Li-Fang Lin, Chang-Shi Chen, et al. 
(2007) Peroxisome proliferator-activated receptor gamma independent 
suppression of androgen receptor expression by troglitazone mechanism 
and pharmacologic exploitation. Cancer Res 67(7): 3229-3238.
6. Shiau CW, Chih-Cheng Yang, Samuel K Kulp, Kuen-Feng Chen, Chang-Shi 
Chen, et al. (2005) Thiazolidenediones mediate apoptosis in prostate 
cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions 
independently of PPAR-gamma. Cancer Research 65(4): 1561-1569.
7. Qin L, Chen Gong, An-Min Chen, Feng-Jing Guo, Fei Xu, et al. (2014) 
Peroxisome proliferator-activated receptor gamma agonist rosiglitazone 
inhibits migration and invasion of prostate cancer cells through 
inhibition of the CXCR4/CXCL12 axis. Molecular Medicine Reports 
10(2): 695-700.
8. Moss PE, BE Lyles, LV Stewart (2010) The PPARgamma ligand ciglitazone 
regulates androgen receptor activation differently in androgen 
dependent versus androgen-independent human prostate cancer cells. 
Exp Cell Res 316(20): 3478-3488.
9. Ahmad I, Ernest Mui, Laura Galbraith, Rachana Patel, Ee Hong Tan, et 
al. (2016) Sleeping Beauty screen reveals Pparg activation in metastatic 
prostate cancer. Proceedings of the National Academy of Sciences of the 
United States of America 113(29): 8290-8295.
10. Rogenhofer S, Jörg Ellinger, Philip Kahl, Christine Stoehr, Arndt 
Hartmann, et al. (2012) Enhanced expression of peroxisome proliferate 
activated receptor gamma (PPAR-gamma) in advanced prostate cancer. 
Anticancer Res 32(8): 3479-3483.
11. Segawa Y, Rikio Yoshimura, Taro Hase, Tatsuya Nakatani, Seiji Wada, 
et al. (2002) Expression of peroxisome proliferator-activated receptor 
(PPAR) in human prostate cancer. The Prostate 51(2): 108-116.
12. Matsuyama M, R Yoshimura (2008) Peroxisome Proliferator-Activated 
Receptor-gamma Is a Potent Target for Prevention and Treatment in 
Human Prostate and Testicular Cancer. PPAR Res p. 249849.
13. Nakamura Y, Takashi Suzuki, Akira Sugawara, Yoichi Arai, Hironobu 
Sasano,  et al. (2009) Peroxisome proliferator-activated receptor gamma 
in human prostate carcinoma. Pathol Int 59: 288-293.
14. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, et al. (1995) 
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte 
determination factor PPAR gamma. Cell 83(5): 803-812.
15. Fukushima M (1990) Prostaglandin J2-anti-tumour and anti-viral 
activities and the mechanisms involved. Eicosanoids 3(4): 189-199.
16. Butler R, Mitchell SH, Tindall DJ, Young CY (2000) Nonapoptotic 
cell death associated with S-phase arrest of prostate cancer cells 
via the peroxisome proliferator-activated receptor gamma ligand, 
15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 11(1): 49-61.
17. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, et al. (1998) 
Ligand for peroxisome proliferator-activated receptor gamma 
Citation: Xi Jin, Bandar A. Alenezi, Gang He, Hongwen Ma, Qiang Wei, and Youqiang Ke*. Peroxisome Proliferator-Activated Receptor Gamma 
(Pparγ) and Prostate Cancer. Open Acc J Oncol Med 5(2)- 2021. OAJOM.MS.ID.000206. DOI: 10.32474/OAJOM.2021.05.000206
                                                                                                                                                          Volume 5 - Issue 2 Copyrights @ Professor Youqiang Ke, et al.Open Acc J Oncol Med
530
(troglitazone) has potent antitumor effectagainst human prostate 
cancer both in vitro and in vivo. Cancer Res 58(15): 3344-3352.
18. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, et al. (2000) 
Down-regulation of prostate-specific antigen expression by ligands for 
peroxisome proliferator-activated receptor gamma in human prostate 
cancer. Cancer Res 60: 5494-5498.
19. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, et al. (2000) Effects of 
ligand activation of peroxisome proliferator-activated receptor gamma 
in human prostate cancer. Proc Natl Acad Sci USA 20 97(20): 10990-
10995.
20. Yang CC, Wang YC, Wei S, Lin LF, Chen CS, et al. (2007) Peroxisome 
proliferator-activated receptor gamma-independent suppression 
of androgen receptor expression by troglitazone mechanism and 
pharmacologic exploitation. Cancer Res 67(7): 3229-3238.
21. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, et al. (2005) 
Thiazolidenediones mediate apoptosis in prostate cancer cells in 
part through inhibition of Bcl-xL/Bcl-2 functions independently of 
PPAR-gamma. Cancer Res 65(4): 1561-1569.
22. Qin L, Gong C, Chen AM, Guo FJ, Xu F, et al. (2014) proliferator-activated 
receptor gamma agonist rosiglitazone inhibits migration and invasion of 
prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Mol 
Med Rep 10(2): 695-700.
23. Qin L, Ren Y, Chen AM, Guo FJ, Xu F, et al. (2014) Peroxisome 
proliferator-activated receptor γ ligands inhibit VEGF-mediated 
vasculogenic mimicry of prostate cancer through the AKT signaling 
pathway. Mol Med Rep 10: 276-282.
24. Moss PE, Lyles BE, Stewart LV (2010) The PPARγ ligand 
ciglitazone regulates androgen receptor activation differently in 
androgen-dependent versus androgen-independent human prostate 
cancer cells. Exp Cell Res 316: 3478-3488.
25. Elix C, Pal SK, Jones JO (2018) The role of peroxisome proliferator-
activated receptor gamma in prostate cancer. Asian J Androl 20: 238-
243.
26. Bao Z, Malki MI, Forootan SS, Adamson J, Forootan FS, et al. (2013) A 
novel cutaneous fatty acid-binding protein-related signaling pathway 
leading to malignant progression in prostate cancer cells. Genes Cancer 
4: 297-314.
27. Forootan FS, Forootan SS, Gou X, Yang J, Liu B, et al. (2016) Fatty acid 
activated PPARgamma promotes tumorigenicity of prostate cancer cells 
by up regulating VEGF via PPAR responsive elements of the promoter. 
Oncotarget 7: 9322-9339.
28. Al-Jameel W, Gou X, Jin X, Zhang J, Wei Q, et al. (2019) Inactivated FABP5 
suppresses malignant progression of prostate cancer cells by inhibiting 
the activation of nuclear fatty acid receptor PPARγ. Genes and Cancer 
10: 80-96
29. Al-Jameel W, Gou X, Forootan SS, Al Fayi MS, Rudland PS, et al. (2017) 
Inhibitor SBFI26 suppresses the malignant progression of castration-
resistant PC3-M cells by competitively binding to oncogenic FABP5. 
Oncotarget 8(19): 31041-31056.
30. Butler R, Mitchell SH, Tindall DJ, Young CY (2000) Nonapoptotic cell 
death associated with S-phase arrest of prostate cancer cells via the 
peroxisome proliferator-activated receptor ga-mma ligand, 15-deoxy-
delta12,14-prostaglandin J2. Cell Growth Differ 11(1): 49-61.
31. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP (2000) 
Down-regulation of prostate-specific antigen expression by ligands for 
peroxisome proliferator-activated receptor gamma in human prostate 
cancer. Cancer Res 60: 5494-5498.
32. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, et al. (1998) 
Ligand for peroxisome proliferator-activated receptor gamma 
(troglitazone) has potent antitumor effect against human prostate 
cancer both in vitro and in vivo. Cancer Res 58(15): 3344-3352.
33. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, et al. (2000) Effects of 
ligand activation of peroxisome proliferator-activated receptor gamma 
in human prostate cancer. Proc Natl Acad Sci U S A 20 97(20): 10990-
10995.
34. Qin L, Gong C, Chen AM, Guo FJ, Xu F, et al. (2014) Peroxisome 
proliferator-activated receptor gamma agonist rosiglitazone inhibits 
migration and invasion of prostate cancer cells through inhibition of the 
CXCR4/CXCL12 axis. Mol Med Rep 10(2): 695-700.
35. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, et al. (2005) 
Thiazolidenediones mediate apoptosis in prostate cancer cells in part 
through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR-
gamma. Cancer Res 65(4): 1561-1569.
36. Yang CC, Wang YC, Wei S, Lin LF, Chen CS, et al. (2007) Peroxisome 
proliferator-activated receptor gamma-independent suppression 
of androgen receptor expression by troglitazone mechanism and 
pharmacologic exploitation. Cancer Res 67(7): 3229-3238.
37. Ahmad I, Mui E, Galbraith L, Patel R, Tan EH, et al. (2016) Sleeping Beauty 
screen reveals Pparg activation in metastatic prostate cancer. Proc Natl 
Acad Sci U S A 113(29): 8290-8295.
38. Rogenhofer S, Ellinger J, Kahl P, Stoehr C, Hartmann A, et al. (2012) 
Enhanced expression of peroxisome proliferate-activated receptor 
gamma (PPAR-gamma) in advanced prostate cancer. Anticancer Res 
32(8): 3479-3483.
39. Segawa Y, Yoshimura R, Hase T, Nakatani T, Wada S, Kawahito Y, et al. 
(2002) Expression of peroxisome proliferator-activated receptor (PPAR) 
in human prostate cancer. Prostate 51(2): 108-116.
40. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR 
gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 
8(10): 1224-1234.
41. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in 
fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 
79(7): 1147-1156.
42. Strand DW, Jiang M, Murphy TA, Yi Y, Konvinse KC, et al. (2012) 
PPARgamma isoforms differentially regulate metabolic networks to 
mediate mouse prostatic epithelial differentiation. Cell Death Dis 3(8): 
e361.
Citation: Xi Jin, Bandar A. Alenezi, Gang He, Hongwen Ma, Qiang Wei, and Youqiang Ke*. Peroxisome Proliferator-Activated Receptor Gamma 
(Pparγ) and Prostate Cancer. Open Acc J Oncol Med 5(2)- 2021. OAJOM.MS.ID.000206. DOI: 10.32474/OAJOM.2021.05.000206
                                                                                                                                                          Volume 5 - Issue 2 Copyrights @ Professor Youqiang Ke, et al.Open Acc J Oncol Med
531
Open Access Journal of Oncology  
and Medicine
 
Assets of Publishing with us
• Global archiving of articles
• Immediate, unrestricted online access
• Rigorous Peer Review Process
• Authors Retain Copyrights
• Unique DOI for all articles
This work is licensed under Creative
Commons Attribution 4.0 License
To Submit Your Article Click Here:       Submit Article
DOI: 10.32474/OAJOM.2021.05.000206
